{"product_id":"ubx-vrio-analysis","title":"Unity Biotechnology, Inc. (UBX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Unity Biotechnology, Inc. (UBX)'s market position with this razor-sharp VRIO analysis. We've dissected its core competencies against the criteria of Value, Rarity, Inimitability, and Organization to deliver a distilled summary of its true competitive advantage. Don't just wonder what makes Unity Biotechnology, Inc. (UBX) tick - read on to see the definitive verdict on its sustainability.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eUnity Biotechnology, Inc. (UBX) - VRIO Analysis: \u003cstrong\u003e1. UBX1325 (Foselutoclax) Clinical Data Package (DME)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core asset of a company that has essentially paused operations, so the value of the UBX1325 data package is paramount right now. The primary value driver is the complete \u003cstrong\u003e36-week\u003c\/strong\u003e data from the Phase 2b ASPIRE trial in Diabetic Macular Edema (DME). This data package, showing non-inferiority to the standard-of-care aflibercept in a key subgroup, is what any potential buyer or licensee is paying for.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the data points driving that value:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMean BCVA gain at 36 weeks: \u003cstrong\u003e+5.5\u003c\/strong\u003e ETDRS letters.\u003c\/li\u003e\n\u003cli\u003eSubgroup outperformance: Patients with CST \u0026lt;\u003cstrong\u003e400\u003c\/strong\u003e microns (about \u003cstrong\u003e60%\u003c\/strong\u003e of the \u003cstrong\u003e52\u003c\/strong\u003e-patient study) showed superior results.\u003c\/li\u003e\n\u003cli\u003ePrimary endpoint miss: Failed at weeks 20\/24 (\u003cstrong\u003e88%\u003c\/strong\u003e CI vs. \u003cstrong\u003e90%\u003c\/strong\u003e threshold).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: High\u003c\/strong\u003e. The non-inferiority at week \u003cstrong\u003e36\u003c\/strong\u003e against aflibercept in a difficult-to-treat population is the key to unlocking a deal, whether it’s an asset sale or a licensing agreement. This data is the only thing keeping the lights on, metaphorically speaking, given the cash position of only \u003cstrong\u003e$16.9 million\u003c\/strong\u003e as of March 31, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Medium\u003c\/strong\u003e. Sure, other senolytics are out there, but this is late-stage, head-to-head data against a blockbuster drug. That specific clinical proof point is rare in the current market, but the underlying science - inhibiting BCL-xL - is known territory for competitors.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: High\u003c\/strong\u003e. Competitors can’t just run a duplicate trial tomorrow; replicating the specific trial execution, patient enrollment, and achieving that exact \u003cstrong\u003e36-week\u003c\/strong\u003e outcome is tough. Still, the mechanism itself isn't a trade secret, so the knowledge is imitable, even if the data package is not.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Low\u003c\/strong\u003e. This is the big hurdle. Unity Biotechnology effectively dissolved its operational structure, laying off its entire workforce in May 2025. The company is relying on former executives as consultants to manage the wind-down and explore strategic alternatives, which cost about \u003cstrong\u003e$3.7 million\u003c\/strong\u003e in severance. Exploitation of the data package relies entirely on an external buyer, not internal execution.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary\u003c\/strong\u003e. The advantage is entirely vested in the data package itself. It’s a ticking clock; every month that passes without a deal, the value erodes, especially since the initial primary endpoint miss at weeks 20\/24 casts a shadow. The company needs a transaction before its cash runs out, which was estimated to be Q4 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Supporting Metric\/Fact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eNon-inferiority to aflibercept at week \u003cstrong\u003e36\u003c\/strong\u003e in DME patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003ctd\u003eLate-stage, head-to-head trial data against standard-of-care.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eUnderlying BCL-xL mechanism is known; trial execution is hard to replicate.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eWorkforce effectively dissolved in May 2025; reliance on external buyers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eAdvantage tied to data that depreciates without a deal; primary endpoint miss at weeks 20\/24.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: draft the 13-week cash flow projection, incorporating the \u003cstrong\u003e$7.3 million\u003c\/strong\u003e Q1 2025 net loss, by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eUnity Biotechnology, Inc. (UBX) - VRIO Analysis: \u003cstrong\u003e2. Foundational Senescence Biology Patent Portfolio\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (for the IP holder)\u003c\/p\u003e\n\u003cp\u003eThe foundational patent portfolio is directed to compositions of matter, use for treating age-related conditions, and methods of manufacture for senolytic agents.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTargeted therapeutic areas include musculoskeletal, ophthalmologic, and pulmonary disorders.\u003c\/li\u003e\n\u003cli\u003eThe portfolio includes co-owned patent families with the Buck Institute for Research on Aging and the Mayo Clinic.\u003c\/li\u003e\n\u003cli\u003eSpecific granted patents cover methods of inhibiting pathological angiogenesis, relevant to ocular disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset\/Patent Scope\u003c\/td\u003e\n\u003ctd\u003eExpected Expiration (Excluding Extensions)\u003c\/td\u003e\n\u003ctd\u003eCo-Assignees\/Partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUBX0101 and UBX1967 Related Patents\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e2032\u003c\/strong\u003e to \u003cstrong\u003e2035\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eVarious\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChiral Synthesis Method for UBX0101\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2037\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUnity Biotechnology, Inc. (Owned)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBcl-2\/xL Inhibitors for Neurodegenerative Diseases\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2035\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBuck Institute, Mayo Clinic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSenolytic Agents for Age-Related Eye Conditions (Example Grant)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2044\u003c\/strong\u003e (Based on Patent Number 11865123B2 granted Jan 9, 2024, filed Aug 25, 2021)\u003c\/td\u003e\n\u003ctd\u003eUnity Biotechnology, Inc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe historical investment in generating this intellectual property is evidenced by prior Research and Development expenditures, such as \u003cstrong\u003e$20.1 million\u003c\/strong\u003e for the year ended December 31, 2023, decreasing to \u003cstrong\u003e$13.0 million\u003c\/strong\u003e for the year ended December 31, 2024.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company reported cash, cash equivalents, and marketable securities totaling \u003cstrong\u003e$23.2 million\u003c\/strong\u003e as of December 31, 2024.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities totaled \u003cstrong\u003e$16.9 million\u003c\/strong\u003e as of March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eNet loss for the twelve months ended December 31, 2024, was \u003cstrong\u003e$26.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUnity Biotechnology, Inc. (UBX) - VRIO Analysis: \u003cstrong\u003e3. Exclusive UCSF Alpha-Klotho License\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe license was executed on \u003cstrong\u003eMay 29, 2019\u003c\/strong\u003e, granting worldwide, exclusive rights to UCSF Intellectual Property relating to the use of alpha-Klotho protein for cognitive decline treatment.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe potential value is supported by preclinical data showing lifespan extension in murine models:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eKlotho overexpression extended male mouse lifespan by up to \u003cstrong\u003e30.8%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eKlotho overexpression extended female mouse lifespan by up to \u003cstrong\u003e19%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eHigher circulating Klotho levels are associated with improved cognitive and physical outcomes in older adults.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eStatistical correlation data regarding age and Klotho levels:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Group\u003c\/td\u003e\n\u003ctd\u003eSample Size (n)\u003c\/td\u003e\n\u003ctd\u003eFinding\/Correlation\u003c\/td\u003e\n\u003ctd\u003eStatistical Measure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthy Adults (18–85 years)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e346\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSerum $\\alpha$-Klotho levels showed negative correlation with age\u003c\/td\u003e\n\u003ctd\u003eP \u0026lt; \u003cstrong\u003e.001\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOlder Adults (55–85 years)\u003c\/td\u003e\n\u003ctd\u003ePart of \u003cstrong\u003e346\u003c\/strong\u003e cohort\u003c\/td\u003e\n\u003ctd\u003eLowest serum $\\alpha$-Klotho levels observed\u003c\/td\u003e\n\u003ctd\u003eP \u0026lt; \u003cstrong\u003e.01\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHypertensive vs. Non-Hypertensive (Older)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e109\u003c\/strong\u003e total\u003c\/td\u003e\n\u003ctd\u003eHypertensive Klotho: \u003cstrong\u003e0.303 $\\pm$ 0.096\u003c\/strong\u003e vs. Non-Hypertensive Klotho: \u003cstrong\u003e0.489 $\\pm$ 0.216\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eP \u0026lt; \u003cstrong\u003e.01\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe asset is characterized by exclusivity granted by the university license.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe agreement grants \u003cstrong\u003eworldwide, exclusive rights\u003c\/strong\u003e to UCSF IP.\u003c\/li\u003e\n\u003cli\u003eThe $\\alpha$-Klotho protein was initially identified in mouse studies in \u003cstrong\u003e1997\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe KL-VS variant of the Klotho gene, associated with higher protein levels, was found in a significantly higher proportion in older adults (age \u003cstrong\u003e66-88\u003c\/strong\u003e) compared to younger adults (OR: \u003cstrong\u003e1.564\u003c\/strong\u003e, 95% CI (1.126– 2.174); P=\u003cstrong\u003e0.008\u003c\/strong\u003e) in one cohort.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe exclusivity is legally enforced via the license agreement, which was subsequently sublicensed.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgreement Date\u003c\/td\u003e\n\u003ctd\u003eLicensee\u003c\/td\u003e\n\u003ctd\u003eScope of Rights Transferred\u003c\/td\u003e\n\u003ctd\u003eLegal Enforceability Basis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMay 29, 2019\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUnity Biotechnology (from UCSF)\u003c\/td\u003e\n\u003ctd\u003eWorldwide, exclusive rights to UCSF IP\u003c\/td\u003e\n\u003ctd\u003eLicense Agreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eDecember 20, 2021\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJocasta Neuroscience (from UBX)\u003c\/td\u003e\n\u003ctd\u003eExclusive agreement for development and commercialization\u003c\/td\u003e\n\u003ctd\u003eExclusive Agreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe value realization is structured through the subsequent sublicensing agreement with Jocasta Neuroscience, effective \u003cstrong\u003eDecember 20, 2021\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUBX receives an \u003cstrong\u003eupfront cash payment\u003c\/strong\u003e from Jocasta.\u003c\/li\u003e\n\u003cli\u003eUBX is entitled to additional payments based on \u003cstrong\u003edevelopment milestones\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUBX is entitled to additional payments based on \u003cstrong\u003eapproval milestones\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUBX is entitled to \u003cstrong\u003esales-based royalties\u003c\/strong\u003e, per indication.\u003c\/li\u003e\n\u003cli\u003eJocasta is required to make all payments due to UCSF from UBX under the original UCSF License.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage stems from the legally defensible, exclusive rights to the intellectual property.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe initial license grants \u003cstrong\u003eworldwide, exclusive rights\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe asset is tied to a recently issued patent covering methods of use.\u003c\/li\u003e\n\u003cli\u003eThe sublicensing agreement allows UBX to share in the upside economics in a \u003cstrong\u003ecapital-efficient manner\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUnity Biotechnology, Inc. (UBX) - VRIO Analysis: \u003cstrong\u003e4. Tie2\/Anti-VEGF Bispecific \u0026amp; Tie2 Agonistic Antibody Assets\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Medium. These represent pipeline diversification beyond UBX1325, offering potential value to a partner with an existing ophthalmology franchise looking to build out their pipeline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium. Other companies are working on Tie2 pathways, but these specific, pre-clinical\/early-stage candidates are unique to the UBX portfolio.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium. The underlying science is known, but the specific molecular constructs are proprietary until disclosed or sold.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low. These assets are currently stalled due to the corporate wind-down and require external capital to advance past the current stage. The company reported cash, cash equivalents and marketable securities of \u003cstrong\u003e$16.9 million\u003c\/strong\u003e as of March 31, 2025, and subsequently filed for voluntary dissolution in September 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Value is speculative and relies on a buyer seeing near-term development potential.\u003c\/p\u003e\n\u003cp\u003eThe specific assets under this category include UBB 2048 (Tie2\/Anti-VEGF Bispecific) and UBX2050 (Tie2 Agonistic Antibody).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset\u003c\/td\u003e\n\u003ctd\u003eTarget Indication Focus\u003c\/td\u003e\n\u003ctd\u003eDevelopment Stage Mentioned\u003c\/td\u003e\n\u003ctd\u003eKey Preclinical Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUBB 2048\u003c\/td\u003e\n\u003ctd\u003eDiabetic Macular Edema (DME), Wet Age-Related Macular Degeneration (AMD)\u003c\/td\u003e\n\u003ctd\u003eClinical candidate molecule\u003c\/td\u003e\n\u003ctd\u003eStrong Tie2 pathway activation and inhibition of VEGF pathways\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUBX2050\u003c\/td\u003e\n\u003ctd\u003eDiseases of vascular permeability (e.g., Chronic Kidney Disease, Diabetic Nephropathy)\u003c\/td\u003e\n\u003ctd\u003eClinical candidate molecule\u003c\/td\u003e\n\u003ctd\u003eActivated Tie2 signaling with potency comparable to angiopoietin-1 in vitro\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific preclinical data points supporting the potential value include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUBX2050 was administered to mice via the intraperitoneal route at a dose of \u003cstrong\u003e10 mg\/kg\u003c\/strong\u003e in a laser-induced choroidal neovascularization model.\u003c\/li\u003e\n\u003cli\u003eUBB 2048 demonstrated efficacy in models of retinal disease.\u003c\/li\u003e\n\u003cli\u003eUBX2050 demonstrated strong Tie2 pathway activation with a clinical candidate molecule.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUnity Biotechnology, Inc. (UBX) - VRIO Analysis: \u003cstrong\u003e5. Residual Cash and Marketable Securities (Post-Restructuring)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High. This is the most tangible asset for current shareholders.\u003c\/p\u003e\n\u003cp\u003eCash, cash equivalents and marketable securities totaled \u003cstrong\u003e$16.9 million\u003c\/strong\u003e as of March 31, 2025. UNITY believed this amount was sufficient to fund operations into the \u003cstrong\u003efourth quarter of 2025\u003c\/strong\u003e. The net loss for the three months ended March 31, 2025, was \u003cstrong\u003e$7.3 million\u003c\/strong\u003e, with cash used in operations during that period at \u003cstrong\u003e$6.4 million\u003c\/strong\u003e. Stockholders approved the Plan of Complete Liquidation and Dissolution on \u003cstrong\u003eSeptember 18, 2025\u003c\/strong\u003e, and the Certificate of Dissolution was filed on \u003cstrong\u003eSeptember 26, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Marketable Securities (03\/31\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Used in Operations (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Operational Runway (Pre-Dissolution)\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ4 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Cash is common, but the net amount available for distribution post-restructuring is the specific figure of interest.\u003c\/p\u003e\n\u003cp\u003eThe specific figure of interest involves the net amount available after significant wind-down expenditures, such as the lease termination obligations.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLease Termination Prepaid Rent Obligation: approximately \u003cstrong\u003e$3.65 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eBreakdown of Lease Payment: \u003cstrong\u003e$2.75 million\u003c\/strong\u003e paid in cash concurrently with execution and right to draw down a \u003cstrong\u003e$0.90 million\u003c\/strong\u003e letter of credit (LC).\u003c\/li\u003e\n\u003cli\u003eSublease Termination Cash Received: \u003cstrong\u003e$0.20 million\u003c\/strong\u003e, obligated to be paid to the landlord.\u003c\/li\u003e\n\u003cli\u003eSublease Termination LC Received: Right to draw down a \u003cstrong\u003e$0.73 million\u003c\/strong\u003e LC, obligated to be paid to the landlord.\u003c\/li\u003e\n\u003cli\u003eContingent Landlord Claim on Asset Monetization: \u003cstrong\u003e25%\u003c\/strong\u003e of cash consideration up to a cap of \u003cstrong\u003e$26.9 million\u003c\/strong\u003e, reduced by prepaid rent amounts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Not Applicable. This is a balance sheet item, not a capability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Medium. The finance team (or advisors) must execute the final distribution plan accurately.\u003c\/p\u003e\n\u003cp\u003eThe organization must adhere to the Plan of Complete Liquidation and Dissolution approved by stockholders on \u003cstrong\u003eSeptember 18, 2025\u003c\/strong\u003e. As of \u003cstrong\u003eJuly 25, 2025\u003c\/strong\u003e, there were \u003cstrong\u003e17,212,172\u003c\/strong\u003e shares of Common Stock outstanding. The company’s common stock was suspended from Nasdaq on \u003cstrong\u003eJuly 9, 2025\u003c\/strong\u003e, and delisted on \u003cstrong\u003eAugust 16, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This is a finite resource that will be depleted upon final liquidation.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eUnity Biotechnology, Inc. (UBX) - VRIO Analysis: \u003cstrong\u003e6. Intellectual Property Rights to UBX1325 Mechanism (BCL-xL Inhibition)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High. The preclinical data showing UBX1325 preferentially eliminated senescent cells by targeting BCL-xL is a key scientific finding for future senolytic development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium. Targeting BCL-xL is a known approach, with 29 investigational drugs for the Bcl-xl target as of December 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium. Competitors can pursue BCL-xL, but they would need to replicate the efficacy data or license this specific IP.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low. The knowledge is documented, but the internal team that validated it is gone, evidenced by a reduction in force and executive consulting roles in May 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (for the IP holder). The specific data package supporting the mechanism is a defensible asset.\u003c\/p\u003e\n\u003cp\u003eQuantitative support for the IP's value is derived from clinical outcomes and financial stewardship:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUBX1325 Mean BCVA Change (24 Weeks)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+5.2\u003c\/strong\u003e ETDRS letters\u003c\/td\u003e\n\u003ctd\u003eASPIRE Phase 2b Trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUBX1325 Mean BCVA Change (36 Weeks)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+5.5\u003c\/strong\u003e ETDRS letters\u003c\/td\u003e\n\u003ctd\u003eASPIRE Phase 2b Trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASPIRE Study Enrollment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e52\u003c\/strong\u003e subjects\u003c\/td\u003e\n\u003ctd\u003ePhase 2b Trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCL-xL Patent Family Expiration (Neuro)\u003c\/td\u003e\n\u003ctd\u003eExpected 2035\u003c\/td\u003e\n\u003ctd\u003eExcluding adjustments\/extensions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.99 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the year ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe intellectual property is protected by patent families expected to expire in 2035 and 2036, excluding potential extensions.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUBX1325 demonstrated non-inferiority to aflibercept at week 36 in the ASPIRE study.\u003c\/li\u003e\n\u003cli\u003ePreclinical studies demonstrated that targeting BCL-xL with UBX1325 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses were $2.8 million for the three months ended September 30, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUnity Biotechnology, Inc. (UBX) - VRIO Analysis: \u003cstrong\u003e7. Completed ASPIRE Trial Infrastructure\/Data Management\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Medium. The established, multi-center, randomized, active-controlled trial infrastructure and the resulting clean, audited data set are valuable for any buyer wanting to run follow-on studies without starting from scratch.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium. Running a successful, large-scale Phase 2b trial is a significant hurdle that has been cleared.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium. Competitors can run trials, but they cannot easily acquire this specific, completed, and analyzed dataset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low. The infrastructure is now dormant, requiring external consultants to manage data access and transfer. The Company is implementing a reduction in force affecting all of its workforce, with certain \u003cstrong\u003econsulting arrangements\u003c\/strong\u003e in place to close down the ASPIRE study.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The value is in the completeness of the data, which fades if not quickly transferred to a new owner.\u003c\/p\u003e\n\u003cp\u003eThe ASPIRE Phase 2b study was a \u003cstrong\u003emulti-center\u003c\/strong\u003e, randomized, double-masked, active-controlled evaluation of UBX1325 versus aflibercept in patients with Diabetic Macular Edema (DME).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Parameter\u003c\/td\u003e\n\u003ctd\u003eDetail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Design\u003c\/td\u003e\n\u003ctd\u003ePhase 2b, Randomized, Double-Masked, Active-Controlled\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Subjects Enrolled\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e52\u003c\/strong\u003e subjects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRandomization Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1:1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTreatment Arms\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10 μg\u003c\/strong\u003e UBX1325 vs. \u003cstrong\u003e2 mg\u003c\/strong\u003e Aflibercept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Frequency\u003c\/td\u003e\n\u003ctd\u003eEvery \u003cstrong\u003eeight weeks\u003c\/strong\u003e for \u003cstrong\u003esix months\u003c\/strong\u003e after randomization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData Readouts\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e24 weeks\u003c\/strong\u003e and \u003cstrong\u003e36 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey statistical outcomes from the completed data points include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMean change in Best-Corrected Visual Acuity (BCVA) for UBX1325 at 24 weeks: \u003cstrong\u003e+5.2 ETDRS letters\u003c\/strong\u003e from baseline.\u003c\/li\u003e\n\u003cli\u003eMean change in BCVA for UBX1325 at 36 weeks: \u003cstrong\u003e+5.5 ETDRS letters\u003c\/strong\u003e from baseline.\u003c\/li\u003e\n\u003cli\u003eNon-inferiority to aflibercept achieved at week \u003cstrong\u003e36\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePrimary endpoint (non-inferiority on the average of weeks \u003cstrong\u003e20\u003c\/strong\u003e and \u003cstrong\u003e24\u003c\/strong\u003e) achieved 88% confidence interval versus a 90% threshold.\u003c\/li\u003e\n\u003cli\u003eUBX1325 was numerically superior to aflibercept at \u003cstrong\u003e7 out of 10\u003c\/strong\u003e time points in a pre-specified population with moderately aggressive disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUnity Biotechnology, Inc. (UBX) - VRIO Analysis: \u003cstrong\u003e8. Residual Corporate Assets (Minimal)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Low. This includes minimal consulting agreements and the rights to any remaining sublease consideration (e.g., \u003cstrong\u003e$0.73 million\u003c\/strong\u003e letter of credit from a subtenant mentioned in the lease termination). The monetization of corporate assets is subject to a landlord clawback provision.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. These are minor, administrative assets typical of a winding-down process.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Not Applicable. These are contractual rights.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low. Managed by the remaining legal\/advisory team.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None. These are just final clean-up items.\u003c\/p\u003e\n\u003cp\u003eThe financial components related to the lease and sublease termination, which represent the most quantifiable residual items, are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eItem\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubtenant Payment Received by Unity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.20 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePaid concurrently with Sublease Termination Agreement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubtenant Letter of Credit Granted to Unity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.73 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFace amount; obligated to be paid to Landlord.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Prepaid Rent Paid to Landlord\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$3.65 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAgreed upon for Lease Termination.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Portion of Prepaid Rent\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.75 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePaid at signing of Lease Termination Agreement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLetter of Credit Portion of Prepaid Rent\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.90 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLetter of credit Unity must draw down for Landlord.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLandlord Clawback Percentage on Asset Monetization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOf cash consideration received by Unity post-termination.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLandlord Clawback Cap\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMaximum amount the landlord is entitled to from asset monetization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe management of these final contractual obligations involves specific administrative steps:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003e$0.20 million\u003c\/strong\u003e received from the subtenant is obligated to be paid to the Landlord within \u003cstrong\u003e10 days\u003c\/strong\u003e of receipt.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eUnity is required to draw down the \u003cstrong\u003e$0.73 million\u003c\/strong\u003e letter of credit and pay the proceeds to the Landlord.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe Lease Termination Agreement terminates the original lease (scheduled to expire December 31, 2029) effective March 31, 2026, unless the Landlord exercises an option to accelerate the termination with at least \u003cstrong\u003e30 days\u003c\/strong\u003e' notice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eUnity Biotechnology, Inc. (UBX) - VRIO Analysis: \u003cstrong\u003e9. Historical Scientific\/Clinical Development Know-How\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Medium. The institutional knowledge regarding senolytic drug development, clinical trial design specific to aging diseases, and navigating the FDA for this class of drug is embedded in the departing executive team.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Deep, specialized experience in a nascent field like senolytics is rare; executives like Dr. Ghosh are valuable hires for competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. This know-how walks out the door with the departing personnel, making it hard to capture unless key people are hired by the acquirer.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low. The organization is dissolving, meaning this know-how is de-coupled from the corporate entity.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a human capital asset that is rapidly migrating away from the corporate shell.\u003c\/p\u003e\n\u003cp\u003eFinance: Estimated net cash distribution per share based on Q1 2025 cash of $16.9 million minus estimated wind-down costs of $3.7 million (severance) and $2.75 million (cash portion of lease termination) is calculated using the Q1 2025 weighted-average shares outstanding.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Marketable Securities (as of March 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Severance and Related Wind-Down Costs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Portion of Lease Termination Prepaid Rent\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.75 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Estimated Cash Outflow for Wind-Down\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.45 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Net Cash for Distribution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.45 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeighted-Average Shares Outstanding (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16,870,800\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Net Cash Distribution Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\sim$0.6194\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe departing executive team includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO Anirvan Ghosh, Ph.D.\u003c\/li\u003e\n\u003cli\u003eChief Financial Officer Lynne Sullivan\u003c\/li\u003e\n\u003cli\u003eChief Legal Officer Alex Nguyen\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eHistorical context for scientific know-how includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDr. Ghosh previously oversaw the advance of 10 preclinical programs into the clinic and the execution of studies as advanced as phase 2 clinical proof-of-concept trials at Biogen.\u003c\/li\u003e\n\u003cli\u003eUnity's lead drug candidate is UBX1325 (foselutoclax), a BCL-xL inhibitor for diabetic macular edema (DME).\u003c\/li\u003e\n\u003cli\u003eThe Phase 2b ASPIRE DME study was designed to enroll approximately 50 subjects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company has filed for dissolution, commencing liquidation on September 26, 2025.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516273647765,"sku":"ubx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ubx-vrio-analysis.png?v=1740227136","url":"https:\/\/dcf-model.com\/products\/ubx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}